Prionics Acquires CEDI Diagnostics
Strategic Partnership With Life Science Innovation Centre
Prionics announced the acquisition of CEDI-Diagnostics. The Dutch firm is part of the Wageningen University and Research Centre (Wageningen UR). Through the purchase of CEDI, Prionics will acquire a substantial number of new products and gain rights to commercialise developments made by the research centre. Prionics and Wageningen UR have additionally agreed on a strategic partnership for the development of future innovations in farm animal diagnostics.
"We have acquired a firm with tests proven on the market and we gain access to future developments of a unique global research centre," says Dr Markus Moser, co-CEO of Prionics.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Last viewed contents
Global Vaccine Market Forecast to 2012 - Examine This Global Vaccine Market Forecast to 2012 as the Market is Expected to Emerge as the Fastest Growing Therapy Area in the Next 5 Years

Time needed to sequence key molecules could be reduced from years to minutes - Research demonstrates potential for rapid, accurate glycan sequencing
Pieris achieves milestone payment in Sanofi collaboration
School_counselor
New Merck begins operations
Tympanal_organ
Wolf-Hirschhorn_syndrome
Empa - St. Gallen, Switzerland
Galapagos initiates Phase II trial for GLPG0634 - Proof-of-Concept study designed to assess efficacy in rheumatoid arthritis patients by year end

Nerve cells grow on nanocellulose
Category:Medical_regulation
